Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPH2101 + lenalidomide
- Development stage
- Unknown
- Lead developer
- Innate Pharma
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
IPH2101 + lenalidomide is a combination therapy under investigation for the treatment of multiple myeloma. IPH2101 (also known as 1-7F9) is a monoclonal antibody that targets and blocks inhibitory killer cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells, thereby preventing negative regulatory signals and enhancing NK-cell-mediated cytotoxicity against multiple myeloma cells. Lenalidomide is an immunomodulatory drug that augments NK-cell function, upregulates ligands for activating NK-cell receptors on tumor cells, and exerts antineoplastic, antiangiogenic, and immune-stimulatory effects. The combination aims to synergistically enhance the immune response against multiple myeloma by both blocking inhibitory signals to NK cells (via IPH2101) and boosting their activity (via lenalidomide). This regimen has been evaluated in phase 2 clinical trials for patients with multiple myeloma[1][2][4][7].
- Other names
- lenalidomide
02
Targets
KIR2DL1CRBN (Cereblon)
Beyond the preview
Go deeper on IPH2101 + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPH2101 + lenalidomide.